Octreotide Acetate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

55 API Suppliers, 27 USDMF, 9 CEP/COS, 4 JDMF, 5 EU WC, 1 KDMF, 20 NDC API, 28 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

25 Drugs in Development

25 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

240 FDF Dossiers, 61 FDA Orange Book, 92 Europe, 11 Canada, 48 Australia, 8 South Africa, 20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML, INJECTABLE;INJECTION - EQ 0.1MG BASE/ML, INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.5MG BASE/ML, INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;SUBCUTANEOUS - EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 1 Faran Shimi Pharmaceutical, 1 Gangwal Healthcare, 1 Pfanstiehl, 2 Actylis, 1 BASF, 1 Finar, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 11 Chewable & Orodispersible Aids, 10 Direct Compression, 10 Taste Masking, 7 Parenteral, 7 Disintegrants & Superdisintegrants, 5 Co-Processed Excipients, 3 Granulation, 1 Solubilizers, 1 Topical, 1 API Stability Enhancers, 1 Thickeners and Stabilizers